Clinical Trial

The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, single center, single-arm, phase 2 study. The aim of this study is to evaluate the efficacy and safety of Luspatercept for Patients with Lower-risk Myelodysplastic Syndromes (MDS).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-06-21.
Status change: Not Yet Recruiting → Recruiting 2024-03-07
Trial Details
NCT Number NCT05925504
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Collaborators: Beijing Health Alliance Charitable Foundation
Conditions Lower Risk MDS Per IPSS-R
Enrollment 36 participants
Start Date 2023-07-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2024-03-12